Yazar "Şendur, Mehmet Ali Nahit" için listeleme
-
Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
Artaç, Mehmet; Çubukçu, Erdem; Bozkurt, Oktay; Bilici, Ahmet; Çelik, S.; Özçelik, M.; Öven, B.; Şimşek, E.; Geredeli, C.; Karaca, M.; Cil, T.; Harputluoğlu, Hakan; Şendur, Mehmet Ali Nahit; Türk, H. Mehmet; Kefeli, Umut; Alacacıoğlu, Ahmet; Tural, D.; Sakin, A.; Karadurmuş, Nuri; Çevik, Duygu; Dane, Faysal; Gümüş, Mahmut (Elsevier, 2022)Background: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ... -
Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data
Karadurmuş, Nuri; Yıldırım, Emre; Yalçın, Şuayib; Gümüş, Mahmut; Bilir, Cemil; Çubukçu, Erdem; Tanrıkulu Şimşek, Eda; Arslan, Çağatay; Dane, Faysal; Çelik, Sinemiş; Bilici, Ahmet; Şendur, Mehmet Ali Nahit; Öven, Başak Bala; Işıkdoğan, Abdurrahman; Türk, Hacı Mehmet; Karaca, Mustafa; Karabulut, Bülent; Özçelik, Melike; Çevik, Duygu; Kefeli, Umut (Lippincott Williams & Wilkins, 2022)Background: The contribution of metastasectomy to progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced stage colorectal cancer has been demonstrated in clinical trials. However, clinical ... -
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Kahraman, Seda; Karakaya, Serdar; Kaplan, Muhammed Ali; Sezgin Göksu, Sema; Öztürk, Akın; Sucuoğlu İşleyen, Zehra; Hamdard, Jamshid; Yıldırım, Sedat; Şendur, Mehmet Ali Nahit (Nature Research, 2024)Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the ...